July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
June 2025 in “Revista Ciencia Multidisciplinaria CUNORI” Early intervention is crucial for managing blood clotting issues in pregnant women with COVID-19.
June 2025 in “Journal of medical and dental science research.” i-PRF and A-PRF show promise in promoting hair regrowth and improving scalp health in androgenetic alopecia.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
May 2025 in “Plastic & Reconstructive Surgery Global Open” Photothermal biomodulated PRP extends hair graft viability by 2 hours compared to standard solutions.
May 2025 in “International Journal of Trichology” Hair Heat Disease is caused by wet, oily hair and friction in hot, humid conditions.
May 2025 in “Journal of medical and dental science research.” i-PRF and A-PRF are promising treatments for hair regrowth in androgenetic alopecia.
April 2025 in “BMC Chemistry” Thiadiazole chitosan conjugates improve hair manageability, moisture, and protection in conditioners.
March 2025 in “International Journal of Trichology” The combined treatment improved hair growth and scalp health in a patient with scalp alopecia from birth.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
February 2025 in “International Journal of Molecular Sciences” RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
January 2025 in “Heliyon” Tamsulosin and finasteride have similar effects on blood sugar control in men with type 2 diabetes.
December 2024 in “Pakistan Armed Forces Medical Journal” PRP is more effective than Minoxidil for treating alopecia areata.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
November 2024 in “Journal of Investigative Dermatology” Understanding snoRNA regulation may help slow skin aging.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.